Sibele Inácio Meireles

Sibele Inácio Meireles

Auto-generated profile, based on publicly available information

Sibele Inácio Meireles

Hospital Sirio Libanes, Sao Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Clinics
Verified
Journal Article
Open access
GFGustavo S. Fernandes
Gustavo S. Fernandes
DMDaniel F. Marques
Daniel F. Marques
DGDaniel Girardi
Daniel Girardi
MBMaria Ignez F. Braghiroli
Maria Ignez F. Braghiroli
RCRenata A. Coudry
Renata A. Coudry
PHPaulo M. Hoff
Paulo M. Hoff
With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.

20 December 2023 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
SMSibele Inácio Meireles
Sibele Inácio Meireles
MCMariana Vargas Cruz
Mariana Vargas Cruz
CGCarla Daniele de Godoy
Carla Daniele de Godoy
LTLeonardo de Testagrossa
Leonardo de Testagrossa

27 December 2024 in Clinics
Verified
Journal Article
Open access
SMSibele Inácio Meireles
Sibele Inácio Meireles
MCMariana Vargas Cruz
Mariana Vargas Cruz
GIGustavo Palmer Irffi
Gustavo Palmer Irffi
LTLeonardo Abreu Testagrossa
Leonardo Abreu Testagrossa
Mycobacteria infections are caused by species of the Mycobacterium tuberculosis complex (MTB) and other species called Non-Tuberculosis Mycobacteria (NTM). Identification of mycobacteria species is very important to define treatment and it can be achieved by direct culture. However, the lack of clear protocols regarding the use of culture or molecular tests on specimens diagnosed with granulomatous lesions causes delays in the diagnosis of the etiological agents and, consequently, the definition of the right treatment. This work aimed to characterize the incidence of mycobacteria species in pulmonary granulomatous lesions and the contribution of Polymerase Chain Reaction (PCR) in Formalin-Fixed Paraffin-Embedded Tissue (FFPE), direct culture, and Ziehl-Neelsen histological stain to the diagnosis. The authors performed an observational, centralized, and retrospective study in a cohort of 336 cases with pulmonary granulomatous lesions. Mycobacteria were detected by ZNS in 54/323 (16.72 %) and by direct culture in 40/198 (20.20 %). MTB DNA was detected by PCR in 10/57 (17.54 %). Mycobacterial culture results revealed MTB in 26/40 (65.00 %), whereas NTM was detected in 13/40 (32.50 %). NTM was represented by M. avium (n = 4), M. intracellulare (n = 3), M. kansasii (n = 3), M. colombiense (n = 1), M. paraffinicum (n = 1), and M. abscessus subsp. massiliense (n = 1). In conclusion, this study demonstrated that mycobacteria are detected in 16.72 % to 20.20 % of pulmonary granulomatous lesions. Moreover, MTB and NTM were detected in these lesions. The use of different methods for mycobacteria detection, in addition to culture, is complementary and contributes to fastening and increasing the detection of mycobacteria in these lesions.

1 September 2014 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
AFA. Ferreira
A. Ferreira
AGA.S.D.A. Gomes
A.S.D.A. Gomes
PHP.M. Hoff
P.M. Hoff
FCF.P. Costa
F.P. Costa
DSD.F. Saragiotto
D.F. Saragiotto
SMS.I. Meireles
S.I. Meireles
Aim: Cancer treatment has rapidly evolved in the last decades. Research is mainly directed towards the development of targeted treatments based on individual patient and tumor characteristics. A major recent focus has been the use of sequencing tests that focus on targetable gene alterations. Comprehensive cancer genomic testing using Next-Generation Sequencing (NGS) technology is a very fast and efficient tool which identifies a large number of alterations, some of which may prove to be an important aid in therapeutic decision-making. Many challenges exist in the transition of these technologies from research tool to clinical practice. We aimed to investigate the effectiveness of the current NGS technology as an aid in the oncologic treatment at our institution. Methods: We retrospectively evaluated a cohort of 75 cases of patients with solid tumors treated from Nov. 11 until Feb. 14, who had their tumors sent for a commercially available sequencing assay that utilizes clinical grade NGS. We analyzed all patients for the identification of targetable gene alterations, and whether this result led to a change in treatment and final outcome. Results: Sixty-six patients (88%) were eligible for our analysis (47% female). Sixty-two (94%) had an identifiable mutation, and 11 (17%) received treatment directed by the NGS result. Seven of these 11 patients (63%) had their tumor analyzed by specimens from metastatic sites. Only one patient had a significant tumor response, which was achieved after 2 months of directed treatment, with disease progression 4 months later. The median number of treatment lines prior to the NGS test was 3. Conclusions: Current technology already allows us to identify a large number of mutated genes in cancer specimens. However, most of those mutations are not yet drugable. Our results were somewhat disappointing, with less than 10% response among those few who could receive the directed therapy. However, it is important to note that ours was a heavily pretreated population, and that a significant number of the mutations identified might not be real drivers to the tumor growth. The results of our study suggest that the NGS test is still largely investigational, and that its use as a rescue tool for heavily pretreated patients remains questionable. Disclosure: All authors have declared no conflicts of interest.